Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Storytel to acquire streaming service Audiobooks.com – entering the U.S. market

The Storytel Group (“Storytel”), one of the world’s largest audiobook and e-book streaming companies, has signed a definitive agreement to acquire Audiobooks.com from KKR. Audiobooks.com is one of the leading services for audiobook experiences in the U.S. With this acquisition, Storytel extends its trajectory of expansion and profitable growth to the largest English-language audio market in the world.Since launching in 2011, Audiobooks.com has cultivated a strong brand presence in the U.S. audiobook market. With a focus on user experience in top-rated apps for iOS and Android devices,

BioStock: BioInvent’s CMO on new positive data with BI-1206

BioInvent has presented additional positive interim data from the company’s phase I/IIa clinical trial with drug candidate BI-1206 for immunotherapy treatment in patients with non-Hodgkin’s lymphoma. Biostock reached out to the company’s Chief Medical Officer, Andres McAllister, who is excited about seeing clinical responses this early in the trial. He is also very impressed by the quality and long duration of the responses.Read the full interview with Andres McAllister at biostock.se: https://www.biostock.se/en/2021/11/bioinvents-cmo-on-new-positive-data-with-bi-1206/ This is a press

BioStock: Toleranzia advances its projects despite challenges linked to Covid-19

Toleranzia, that develops potentially curative treatments for severe autoimmune diseases, is, like many other companies, affected by the Covid-19 pandemic. The company recently announced that the planned clinical trial of its drug candidate TOL2 will be postponed until the second half of 2023, due to the fact that the unabated global need for Covid-19 vaccine in the world is causing an extensive shortage of materials needed to purify Toleranzia’s drug candidate. BioStock contacted Toleranzia’s CEO Charlotte Fribert to find out how the company is affected by the delay.Read the full interview

Bonava acquires approximately 370 building rights in Umeå

Bonava has signed an agreement to acquire approximately 370 building rights for multi-family housing in Umeå from Motorcentralen. The final purchase price is based on the planned area for housing units and will be paid in conjunction with the zoning plan entering force, on a preliminary basis, in late 2023. The start of construction is planned for 2024.– Bonava has a strong position in Umeå and positive experiences of operating in the municipality. This large land acquisition is in a very attractive location and further strengthens our position, says Fredrik Hemborg, Business Unit President,

Swedbank Robur lowers fees on 10 funds

At the end of October, Swedbank Robur adopted the decision to reduce the fee of 10 of their funds, which involves a fee reduction for the funds of between 0.1- 0.3 percentage points. The reduction is a result of the continuous work to review and ensure a relevant and attractive product offering, as well as further aligning the product offer with the fund company's business strategy which platform is based on simplicity, innovation and sustainability.The purpose of the fee reduction is to ensure an attractive offer to savers and to continue building on a transparent, logical, and easy to

Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021

Poster presentation to highlight the ability of ATOR-1017 to activate and rescue tumor infiltrating exhausted T cells in synergy with PD-1Lund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced new preclinical data highlighting the 4-1BB (CD137) antibody ATOR-1017 including an update on the ongoing phase 1 study. ATOR-1017, a promising candidate for immunotherapy with enormous potential for combination with other immunomodulatory antibodies, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting & Pre-

Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the lead compound targeting CD40 and CEA at SITC Virtual Annual Meeting 2021

Poster Presentation to highlight our Neo-X-Prime™ platform that aims to enable antigen presenting cells to efficiently enhance priming of tumor neoantigen-specific T cells with the goal of overcoming PD-1 resistance in certain tumor typesLund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that data highlighting the efficacy and safety of Neo-X-Prime™ bsAbs and how Alligator’s lead compound targeting CD40 and CEA meets key needs in Immuno-oncology, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting &

OKEA acquires 2.223% in the Ivar Aasen field from Neptune Energy

(Trondheim, 12 November 2021) OKEA ASA (OSE: OKEA) today announces the purchase of 2.223% working interest (WI) in the Ivar Aasen field from Neptune Energy Norge AS (“Neptune”). Total compensation is up to USD 12.7 million dependent on the oil price in 2022. The acquisition will add to OKEA’s current holding of 0.554% WI in Ivar Aasen and increases the ownership share to 2.777% following the transaction. The effective date of the transaction is 1 January 2022.  OKEA’s acquisition of the Ivar Aasen stake is a part of a larger transaction involving M Vest Energy AS (“M Vest”).  In total,

Invitation to presentation of Thunderful Group’s interim report Q3 2021

Thunderful Group invites to a teleconference/audiocast November 16, 2021, 10.30 CET.The interim report for q3 2021 is presented and thereafter there is an opportunity to ask questions. Questions can be posed verbally via the teleconference, or in writing via the audiocast. A recorded version of the presentation will also be available on Thunderful Group's website. The presentation will be held in English. The interim report is published at 07.30 CET November 16, 2021. Present:Brjann Sigurgeirsson, CEOAnders Maiqvist, CFO The teleconference will be available at:SE: +46850558374

Oncopeptides has announced the Nomination Committee

STOCKHOLM — November 12, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2022 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30, along with the Chairman of the Board of Directors.The composition of the Nomination Committee has now been established, and Oncopeptides today announced that the Nomination Committee in respect of the annual general meeting 2022

BioStock: Promising study results for Invent Medic

Urine leakage is a common problem that limits many women’s lives while at the same time being a taboo subject to discuss. Lund-based Invent Medic has developed the Efemia bladder support to reduce worry about Stress Urinary Incontinence. A study testing Efemia in women who experience leakage while running recently presented promising results. BioStock contacted Klara Rasmusson, Customer Success Manager at the company, to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2021/11/promising-study-results-for-invent-medic/This is a press release from BioStock -

PowerCell Sweden AB brings forward the publication of the report for the fourth quarter 2021

PowerCell Sweden AB (publ) has decided to bring forward the publication of the report for the fourth quarter 2021 to 11 February 2022 at 08.30 a.m. CET. The previously announced date for publication was 17 February.For further information, please contact: Richard BerklingCEO, PowerCell Sweden AB (publ)Phone: +46 (0) 31 720 36 20Email: richard.berkling@powercell.se About PowerCell Sweden AB (publ) PowerCell Sweden AB (publ) develops and produces fuel cell stacks and systems for stationary and mobile applications with a world class energy density. The fuel cells are powered by

Interim Report January-September 2021

Deliveries have started, and ChromoGenics improved its earningsThird quarter of 2021 · ChromoGenics began in-house production of its dynamic glass ConverLight® Dynamic at the end of May at a slow rate to reduce the risk of production disruptions. During the quarter, the rate of production was gradually increased with several deliveries to our customers. · After ChromoGenics completed the long-term tests of the in-house dynamic glass ConverLight[® ]Dynamic in mid-June, the top priority has been the post-inspection. Our focus is now on increasing the rate of production step by step in

Scandion Oncology announce cancellation of extraordinary general meeting

Scandion Oncology A/S, today announced that the extraordinary general meeting on Wednesday November 17, 2021, has been cancelled.The contemplated extraordinary general meeting in the Company on November 17, 2021 was initially requested by shareholders representing 5.71% of the registered share capital. The Board of Directors has  now been informed that the request for an extraordinary general meeting with the proposed agenda is no longer supported by shareholders representing at least 5% of the registered share capital. For that reason, the planned extraordinary general meeting is cancelled.

Strong sales growth with a significant improvement in operating income

PowerCell Sweden AB grew its sales by 171 percent during the third quarter 2021, from MSEK 17 to MSEK 45. Operating income improved to MSEK -12 (-28) due to increased sales and strengthened gross margin. Growth was driven by increased demand in all segments.In terms of sales, the third quarter 2021 was yet another very strong quarter for PowerCell Sweden AB and a new record for a single quarter, in terms of both sales and growth. This was the fourth quarter in a row with record sales in absolute numbers in comparison with corresponding quarters previous years. “The disruptions in our

Sleep Cycle interim report July-September 2021: Accelerated growth and important strategic partnership

Net sales increased 20,9% to SEK 48.8m during the third quarter, corresponding to a 30.0% currency adjusted growth rate. The increase was driven by subscription growth of 13.0%, fueled by high efficiency in marketing spending and income related to a partnership that was entered into together with Samsung. In the partnership with Samsung, Sleep Cycle will be integrated in Samsung’s smart watches and becomes part of Samsung’s health offering.Third quarter summary (July-September 2021) · Net sales increased by 20.9 (30.4 July-September 2020) % and totaled SEK 48,759 (40,336) thousand.

Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 2021

Poster presentation to highlight the design of Optimize-1, evaluating mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinomaLund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that the design and scientific rationale of OPTIMIZE-1, Alligator´s phase 2 study (NCT02829099) in 1[st] line metastatic pancreatic cancer in combination with mFOLFIRINOX, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting & Pre-Conference Programs virtually on November 10[th] –

Notice to the Extraordinary General Meeting of Eevia Health Abp

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 9th of December, 2021 at 1.00 pm at the main office of Eevia Health Plc in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12.30 pm.A. Matters on the agenda of the General Meeting At the General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to supervise

Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

Data support Advancement into the ClinicLund, Sweden, and Seattle Washington, November 12, 2021 – Alligator Bioscience AB (“Alligator”) and Aptevo Therapeutics (“Aptevo”) today announces preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor antigen 5T4 will be presented in a poster at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting, taking place virtually and in-person on November 12[th] – 14[th], 2021 in Washington D.C. The poster highlights preclinical datasets as an overview of the potential indication landscape,

Fiskars Corporation - Notification of management's transactions - Ahlström (acquisition)

Fiskars CorporationManagers' transactionsNovember 12, 2021 at 09:15 EET  Fiskars Corporation - Notification of management's transactions Fiskars Corporation has received the following notification pursuant to Article 19 of the Market Abuse Regulation: Fiskars Oyj Abp - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Ahlström, Anja NathaliePosition: Chief Executive OfficerIssuer: Fiskars Oyj AbpLEI: 743700BKTW4EQIVKYY42 Notification type: INITIAL NOTIFICATIONReference number:

Fiskars Corporation - Notification of management's transactions - Siitonen (acquisition)

Fiskars CorporationManagers' transactionsNovember 12, 2021 at 09:15 EET  Fiskars Corporation - Notification of management's transactions Fiskars Corporation has received the following notification pursuant to Article 19 of the Market Abuse Regulation: Fiskars Oyj Abp - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Siitonen, JussiPosition: Chief Financial OfficerIssuer: Fiskars Oyj AbpLEI: 743700BKTW4EQIVKYY42 Notification type: INITIAL NOTIFICATIONReference number: 743700BKTW4EQIVKYY42_

High acquisition pace brought strong growth

Third quarter 2021 · Net revenue increased by 28% to SEK 577 million (450). · Adjusted EBITA increased to SEK 82 million (76), corresponding to an adjusted EBITA margin of 14.2% (16.8). · EBIT amounted to SEK 11 million (73). · Adjusted EBIT amounted to SEK 69 million (73). · Adjusted profit for the period amounted to SEK 4 million (27). · Earnings per share, basic and diluted, totalled SEK -0.45 (0.24). · Cash flow from operating activities amounted to SEK 43 million (38). Costs affecting comparability amounted to SEK 58 million (0) in the third quarter of 2021

Further efficacy data from the COVID-19 clinical Phase I/II study with ABNCoV2 confirms strong positive results

Hørsholm, Denmark, November 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the remaining virus neutralization data, for the two highest dose ranges of 50 μg and 70 μg, have now been published from the COUGH-1 COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine. The headline results met its safety and efficacy endpoints also for these dose ranges, and thus for the study in its entirety.COUGH-1 headline results Positive initial data from the first-in-human study of ABNCoV2, the capsid virus like particle (

Autoliv investing in Japan to optimize footprint for future growth

(Stockholm, Sweden, November 12, 2021) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announced the launch of a Japan footprint optimization plan, including the establishment of a new state of the art production facility in central Japan and phasing out two existing plants. The investment demonstrates Autoliv’s commitment to its customers and to the Japanese market. Supported by Autoliv’s strong engineering and manufacturing capabilities in Japan, we have gained a leading position with Japanese car manufactures across the world. In

There are no items matching the current filter
There are no more items matching the current filter
Back to top